Recruiting

Observational Study

Sponsor:

Wren Laboratories LLC

Code:

NCT07454603

Conditions

Prostate Cancer

Urology

Prostate Cancer (Diagnosis)

Eligibility Criteria

Sex: Male

Age: 45 - 70+

Healthy Volunteers: Not accepted

Interventions

PROSTEST

Study Details

Brief summary:

This prospective observational study will enroll men referred for prostate biopsy due to elevated PSA and/or abnormal digital rectal examination, with or without pre-biopsy MRI. Peripheral blood will be collected prior to biopsy for PROSTest analysis. Biopsy histopathology will serve as the reference standard. PROSTest results will be analyzed blinded to pathology.

Conditions

Prostate Cancer

Urology

Prostate Cancer (Diagnosis)

Study ID

NCT07454603

Start date

Apr 15, 2026

Status verified date

Aug, 2026

Completion date

Jun 1, 2027

Anticipated

Primary completion date

Feb 28, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 45 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • elevated PSA and/or abnormal digital rectal examination

Exclusion Criteria:

  • Previous Prostate cancer diagnosis

Study Design

Enrollment

1500 participants

Anticipated

Interventions and Outcome Measures

Interventions

PROSTEST

BLOOD SAMPLE FOR PROSTEST MEASUREMENT

Primary outcome measure

  • Diagnostic accuracy of the PROSTest to detect prostate cancer at biopsy [ Time Frame: Following completion of the study. Study is anticipated to enroll over a year and be completed within 18 months. Samples will be evaluated at study end. ]

Central Contacts and Locations

Locations

Wren Laboratories

Recruiting

Branford, Connecticut, United States, 06405

Contacts

More Information

Sponsor

Wren Laboratories LLC

Last update posted

Aug 21, 2026

Last verified

Aug, 2026

Keywords

  • BIOPSY
  • MRI
  • PROSTATE CANCER

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Wren Laboratories LLC on 2026-08-21.